Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3857210 Brain Receptor Occupancy PET Study
NCT05292040Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RQ-00466479 in chronic pain, diabetic polyneuropathy (DPN), osteoarthritis (OA) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in brain receptor occupancy (RO) of LY3857210 up to 6 weeks. Started Mar 2022; status: completed.
02
Drugs
RQ-00466479
03
Conditions
chronic paindiabetic polyneuropathy (DPN)osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT05292040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292040.